The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHL
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses the ongoing Phase III SUNMO trial, which is evaluating the safety of mosunetuzumab in combination with polatuzumab vedotin (M-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL; NCT05171647). This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
